Abraxane White Paper Distribution At ASCO Draws FDA Advertising Letter

Celgene says the white paper – which FDA says promotes Abaxane as effective for unapproved uses and superior to Bristol-Myers Squibb’s Taxol – was intended solely for potential business partners interested in nab technology.

Firms need to be more restrictive in how they distribute business development materials at medical conferences, an FDA advertising letter to Celgene Corp.suggests.

In the untitled letter, dated Dec. 23, the agency objects to a white paper about Abraxane...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America